CN102552593A - Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof - Google Patents
Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof Download PDFInfo
- Publication number
- CN102552593A CN102552593A CN2012100186800A CN201210018680A CN102552593A CN 102552593 A CN102552593 A CN 102552593A CN 2012100186800 A CN2012100186800 A CN 2012100186800A CN 201210018680 A CN201210018680 A CN 201210018680A CN 102552593 A CN102552593 A CN 102552593A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- treatment
- pharmaceutical composition
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a Chinese medicinal composition for treating wind-cold-dampness arthralgia and a using method thereof, and belongs to the field of traditional Chinese medicaments. The first aim of the invention is to provide a medicinal composition for treating wind-cold-dampness arthralgia, which consists of unprocessed semen strychni, garden balsam stem, semen brassicae, cinnamon, processed monkshood, raw arisaema consanguineum schott, medcinal evodia fruit, corydalis tuber, clematis root, manchurian wild ginger, borneol and musk. The second aim of the invention is to provide a using method of the medicinal composition for treating wind-cold-dampness arthralgia, which is used for sticking the medicinal composition to an acupuncture point of a human body. The medicinal composition has strong pungent and warm property, generates strong irritation to the acupuncture point, and plays roles in warming yang deficiency and internal organs by virtue of special functions of the point to achieve the function of strengthening body resistance and preventing wind-cold-wetness evil. Meanwhile, the Chinese medicinal composition has the functions of strengthening healthy energy of a human body, improving immunity, repelling internal cold and dampness, so that the attack in winter can be effectively controlled or reduced, and the aim of treating both principal and secondary aspects of disease can be achieved.
Description
Technical field
The present invention relates to the field of Chinese medicines, specifically, relate to a kind of Chinese medicine composition of treating anemofrigid-damp arthralgia.
Background technology
Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, old lumbago and skelalgia etc. are clinical common rheumatisms, have touching difficulty more, characteristics such as severe and migratory arthralgia swells and ache, joint is triped and fall, serious harm human beings'health, the traditional Chinese medical science are referred to as " arthromyodynia ".The description of " wet three gas of wind and cold are assorted extremely, close and be numbness " is just arranged from " interior warp " for arthromyodynia.The arthromyodynia lid is deficient because of the energy and blood of human body negative and positive; Weakened defensive QI, factor affecting such as weather, environment, overwork cause the damp and hot heresy of wind and cold to be taken advantage of a weak point in addition; The stasis of blood stagnate joint, retardance meridians, cause QI and blood being obstructed, muscle arteries and veins lose support, blood vessels stop up and stagnate, coagulate puckery obstructed or strongly fragrant heat-transformation of a specified duration; The numbness that forms of a specified duration; " wind, cold, wet " is its main paathogenic factor, and " void ", " heresy ", " stasis of blood " are that its etiology and pathogenesis is crucial, and is evil because of apoplexy due to deficiency, causes the stasis of blood in the heresy, and the stasis of blood for a long time must be empty, moves in circles, and runs through primary disease all the time.So the primary disease treatment when catching the cause of disease, pathogenesis and paathogenic factor, divides card to distinguish and controls, control with " strengthening vital QI to eliminate pathogenic factors, a surname's numbness collateral dredging ", the disease of can going directly institute, As the medicine took effect, the symptoms lessened.
Medicinal vesiculation is a kind of of Chinese medicine tradition external therapy, promptly in the body surface plaster medicine, makes congested flushing of local skin or foaming, through the effect of medicine acupuncture points on the human body and meridians, reaches the purpose of disease preventing and treating.In the Spring and Autumn and the Warring States Periods " 52 Bingfang ", spread on the record that Baihui acupoint is treated venom with regard to useful sinapism.It moxibustion therapy is gone through number constantly development and perfect of generation, and new breakthrough and progress are all being arranged aspect clinical practice and the theoretical research.According to the principle of " interior warp " taking good care of YANG in spring and summer, at the beginning of annual summer, in, treat the 1st day first day of the last period of the hot season, claims dog days medicinal vesiculation again.In the dog days, weather is hot, and human body space between skin and muscles using pungent drugs for dispersion and bitter drugs for purgation pastes medicine this moment on the acupuncture point; Medicine is prone to get into acupuncture point meridian by skin, and the operation effect through meridian qi and blood arrives relevant internal organs, so as to the adjustment body function; Strengthen resistance against diseases and press the changes of YIN YANG in four seasons growth and decline rule, how prosperous human body is in spring and summer, and hold back winter more; This easy impairment of YANG of the body of prolonged illness, in winter, this not prosperous sun is not enough more; Negative and positive are obviously unbalance, so some diseases increases the weight of in the winter time or brings out, often can obtain special effect and treat in summer in advance.
Doctor trained in Western medicine be mostly to treat according to symptom, and the traditional Chinese medical science is done as a whole consideration with human body when the treatment anemofrigid-damp arthralgia, and Comprehensive Treatment, conditioning have its special advantages.
Summary of the invention
Symptom and pathogeny to anemofrigid-damp arthralgia; The present invention provides a kind of pharmaceutical composition that is used to treat anemofrigid-damp arthralgia, and this pharmaceutical composition has stronger hot using warming therapy property, can produce than strong stimulation the acupuncture point; Specific function by the acupuncture point; Temperature compensation yang deficiency internal organs, thus reach the merit of setting upright, in case wind-cold damp pathogen.
The present invention realizes through following technological means: a kind of pharmaceutical composition that is used to treat anemofrigid-damp arthralgia, its raw material be by Semen Strychni, Herba speranskiae tuberculatae, and Semen Sinapis Albae, Cortex Cinnamomi, Radix Aconiti Preparata, Rhizoma Arisaematis, Fructus Evodiae, Rhizoma Corydalis, Radix Clematidis, Herba Asari, Borneolum Syntheticum, Moschus is formed.
Semen Strychni removing obstruction in the collateral to relieve pain in the side, mass dissipating and swelling eliminating can be attacked rheumatoid arthritis stubborn, the Semen Sinapis Albae outer expectorant stasis of blood of flesh side film of dispelling; The pain relieving of Herba speranskiae tuberculatae relaxing muscles and tendons to promote blood circulation, three herbal medicines are monarch, the repercussive eliminating stagnation, and removing obstruction in the collateral to relieve pain can remove the stupid heresy in deep.It is supporing yang that Cortex Cinnamomi is mended fire, dispersing cold for relieving pain, and the Fructus Evodiae warming spleen and stomach for dispelling cold therapeutic method to keep the adverse QI flowing downwards, the Radix Aconiti Preparata expelling wind and removing dampness, antalgic is used for anemofrigid-damp arthralgia, arthralgia, Rhizoma Arisaematis, drying dampness to eliminate phlegm, mass dissipating and swelling eliminating can help the Semen Sinapis Albae outer expectorant stasis of blood of flesh side film of dispelling; More than four medicines be minister, principal drug assistance dispelling cold by warming the meridian, the blood stasis dispelling of eliminating the phlegm.Rhizoma Corydalis is arrogated to oneself promoting the circulation of QI to relieve pain, and Radix Clematidis is long with expelling wind and removing dampness, and the Herba Asari expelling wind and cold is good especially, and three medicines share and help that the monarch and his subjects' cold expelling removes, wet promoting the circulation of QI to relieve pain, take into account the various pathogenic characteristics of arthromyodynia.Simultaneously, again with Moschus, Borneolum Syntheticum for making, Xin Xiang walks to scurry, priming transdermal table and going into, expelling pathogenic factors from the exterior goes out through space between skin and muscles.All medicines share, and play the effect that expelling wind and cold, removing obstruction in the collateral to relieve pain, clearing away phlegm dehumidifying, expelling pathogenic factors from the exterior are gone out altogether.
The present invention also can do following improvement:
Its raw material comprises in weight portion: Semen Strychni 500-750 part, Herba speranskiae tuberculatae 500-750 part, Semen Sinapis Albae 500-750 part; Cortex Cinnamomi 300-450 part, Radix Aconiti Preparata 300-450 part, Rhizoma Arisaematis 300-450 part; Fructus Evodiae 200-300 part, Rhizoma Corydalis 200-300 part, Radix Clematidis 200-300 part; Herba Asari 100-150 part, Borneolum Syntheticum 100-150 part, Moschus 3-5 part.
Its raw material comprises in weight portion: 500 parts of Semen Strychni, 500 parts of Herba speranskiae tuberculataes, 500 parts of Semen Sinapis Albaes, 300 parts of Cortex Cinnamomis, 300 parts of Radix Aconiti Preparatas, 300 parts of Rhizoma Arisaematis, 200 parts of Fructus Evodiaes, 200 parts of Rhizoma Corydalis, 200 parts of Radix Clematidis, 100 parts of Herba Asaris, 100 parts of Borneolum Syntheticums, 5 parts in Moschus.
Said dosage form is to add excipient after raw material grinds to the powder to be made as unguentum.
Said excipient is a vaseline.
The above-mentioned method for using that is used to treat the pharmaceutical composition of anemofrigid-damp arthralgia is that said pharmaceutical composition is affixed on the human acupoint.
This method for using also can be done following improvement:
After being affixed on said pharmaceutical composition on the human acupoint, keep 2h-3h, paste the medicine place and avoid extruding.Because of individual physique difference, the patient can be scorching hot rubescent according to local appearance after pasting medicine, or slight twinge can be removed the subsides medicine voluntarily.There is scorching hot twinge to feel bad like the part and also can removes medicine in advance.Skin blush occurs and belongs to normal phenomenon behind the subsides medicine, can be coated with ten thousand carburetion outward, causes blister like drug of topical application overlong time, should protect wound surface, avoids scratching infection, can put scald ointment on the skin.Cold water was not being wanted in the position of the drug of topical application in 10 hours.Paste moxibustion same day, cold and cool raw food of fasting and pungent thing.
Whenever used once said pharmaceutical composition at a distance from 10 days, 3 times was 1 course of treatment.
Compared with prior art, the beneficial effect that has of the present invention is:
1) pharmaceutical composition that is used to treat anemofrigid-damp arthralgia of the present invention has stronger hot using warming therapy property, can produce than strong stimulation the acupuncture point, and by the specific function at acupuncture point, temperature compensation yang deficiency internal organs, thus reach the merit of setting upright, in case wind-cold damp pathogen.Simultaneously, to the different parts of insensitive impediment pain, the acupuncture points on the human body around it is carried out medicinal vesiculation; Also can dispel " the flesh side film is outer " cold, wet, all heresies of the stasis of blood; Can enhances human body healthy energy, improve immunity, the cold-damp of volt in dispersing; Thereby control effectively or reduce its outbreak in the winter time, reach the purpose of treating both the principal and secondary aspects of a disease.
When 2) adopting technology of the present invention that the wind cold wetness type patient with rheumatoid arthritis is treated, total effective rate reaches 96.29%, and obvious effective rate reaches 37.04%, and wherein obvious effective rate and matched group relatively have significant difference (P＜0.05); And the treatment group obviously is superior to matched group (P＜0.05) in the improvement of patient's stiff time of pain index, tenderness index, swelling index and morning, obviously is being superior to matched group (P＜0.05) aspect the decline of erythrocyte sedimentation rate index; Treatment group treatment back immunoglobulin has obvious decline (P＜0.05) before the treatment.The present invention has effect preferably aspect the pain of improving rheumatoid arthritis wind cold wetness type patient and the functional activity.
When 3) adopting technology of the present invention that patients with ankylosing spondylitis is treated, total effective rate reaches rate 94.74%, obvious effective rate 42.11%; Wherein obvious effective rate and matched group relatively have significant difference (P＜0.05); And the treatment group pain, tenderness and morning stiff improve aspect obviously be superior to matched group (P＜0.05), be superior to matched group (P＜0.05) aspect the decline of erythrocyte sedimentation rate and CRP, treatment group treatment back immunoglobulin has obvious decline (P＜0.05) before the treatment.The present invention has effect preferably aspect the pain of improving ankylosing spondylitis wind cold wetness type patient and the functional activity.
4) use pharmaceutical composition of the present invention to carry out dog days' medicinal vesiculation control rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, old lumbago and skelalgia etc. clinically and belong to traditional Chinese medical science anemofrigid-damp arthralgia person, total effective rate reaches 95%.
5) pharmaceutical composition that is used to treat anemofrigid-damp arthralgia of the present invention can alleviate rat paw edema, and is remarkable with the placebo group comparing difference; And treatment group, matched group pathological change integration and placebo group comparing difference are remarkable, can alleviate the joint pathology infringement.
The specific embodiment
Below in conjunction with embodiment the present invention is further specified, but the present invention is not caused any restriction.
Embodiment 1
The method for preparing that is used to treat the pharmaceutical composition unguentum of anemofrigid-damp arthralgia of the present invention
Semen Strychni 500 grams, Herba speranskiae tuberculatae 500 grams, Semen Sinapis Albae 500 grams, Cortex Cinnamomi 300 grams, Radix Aconiti Preparata 300 grams; Rhizoma Arisaematis 300 grams, Fructus Evodiae 200 grams, Rhizoma Corydalis 200 grams, Radix Clematidis 200 grams; Herba Asari 100 grams, Borneolum Syntheticum 100 grams, Moschus 5 grams, the back that grinds to the powder adds vaseline 1280 and restrains paste making agent.
Embodiment 2
The present invention is to the experimentation of adjuvant arthritis rat arthritis disease influence
1. experiment material
1.1 laboratory animal
40 of the healthy SD rats at 3～4 monthly ages, body weight 224.5 ± 7.83g, male (Nanfang Medical Univ's Experimental Animal Center provides).
1.2 trial drug and reagent
Trial drug is embodiment 1 a prepared unguentum; Contrast Western medicine group system is with Vitalin Emulgel (Novartis Pharma AG, lot number: 03146).Placebo group is with vaseline ointment (Guangzhou General Hospital Guangzhou Military Command's preparation).Fu Shi Freund's complete adjuvant 10mg/ml (lanoline 15%, liquid paraffin 85%, inactivated vaccine fully grind mixing, by Shanghai Institute of Pharmaceutical Industry's preparation).
2. test method
2.1 modeling method
40 rats are divided 3 groups at random, and wherein experimental group is 15,15 of matched groups, 10 of placebo vaseline groups.The right sufficient sole of the foot intradermal injection Fu Shi Freund's complete adjuvant 0.1ml of rat injected back second day, and swelling appears in the right whole sole of the foot.
2.2 medication
Chinese medicine experimental group: treat simultaneously in experiment beginning in the 1st day modeling, rat is fixed on the special Mus frame, get the ventricumbent position for one group, select DAZHUI acupoint, Liangqiu, acupuncture point, Heding around the right whole sole of the foot joint.And serve as according to confirming the acupuncture point to dissect locating acupoint by bodily mark.After rat acupuncture point surface QUMAO and the sterilization; The circular hole of cutting a diameter 0.5cm in the middle of 2 * 2cm adhesive plaster is attached on the selected acupuncture points on the human body; Circular hole is exposed at the acupuncture point, and the unguentum that contains the 0.05g Semen Sinapis Albae with each every cave is coated on the skin in the circular hole of surface, acupuncture point, and the reuse adhesive plaster is double-deck fixing.Set time is 3h, executes in per 5 days to control 1 time, pastes 5 times one courses of treatment altogether.Each treatment is all carried out between Beijing time 10:00～14:00.
Matched group and placebo group: usage is the 0.1g medicine and is applied to 1cm outward
2The two metapedes of rat surface, the set time is 3h.
2.3 specimen collection and observation index
2.3.1 observe the rat ordinary circumstance
Comprise the mental status, motility, fur, appetite etc.Record at any time changes.
2.3.2 mensuration rat body weight
Weekly with 1 body weight of electronic balance survey and record.
2.3.3 the mensuration of pathological changes swelling degree of the paw
Use special animal volume determination appearance to measure rat bilateral hind leg foot sole of the foot volume, 1 time weekly.Concrete grammar: the location to ankle, is immersed tank from sufficient pawl fully, and through the tee T control water level, the water yield of discharge connects the graduation apparatus reading, is the rat paw volume.Get two hind leg foot sole of the foot volume meansigma methodss and note down, change from volume and judge the variation of suffering from limb swelling degree.
2.3.4 joint tissue pathological observation
(1) joint pathology microsection manufacture: after corresponding observation finishes, put to death rat, get right back ankle joint, place 10% formalin solution fixing.EDTA decalcification then, specimens paraffin embedding slices is put microscope slide, with h and E dyeing, accomplishes pathological section and makes.
(2) pathological observation content and evaluation grade scale: the pathological section of processing, observe in 400 * high power lens visual field.
1. synovial cell proliferation: calculate the cell number of plies of 3 different parts of backing layer, get the cell number of plies of its meansigma methods as the synovial membrane backing layer.No synovial cell proliferation (-); Cell monolayer swelling intensive (+); Two confluent monolayer cells swelling intensive (++); Three layers and above cellular swelling intensive (+++).
2. inflammatory cell infiltration: no inflammatory cell (-); The sparse inflammatory cell (+) that is dispersed in; Comparatively dense inflammatory cell (++); A large amount of inflammatory cells (+++).
3. proliferation of fibrous tissue: no proliferation of fibrous tissue (-); Small amount of fibers hamartoplasia (++); Moderate proliferation of fibrous tissue (++); A large amount of proliferations of fibrous tissue (+++).
4. the huge like cell bag hypertrophy of biting: the no huge like cell hypertrophy (-) of biting; Sparsely be dispersed in the huge like cell of biting and assemble (+); The huge like cell of biting of comparatively dense is assembled (++); A large amount of huge like cells of biting are assembled (+++).
5. articular cartilage is destroyed: no joint cartilage destruction (-); Slight articular cartilage is destroyed (+); The moderate articular cartilage is destroyed (++); Severe articular cartilage destruction (+++).
More than (-) to (+++) the 0-3 branch of scoring respectively.
2.4 statistical procedures
Total data all with means standard deviation
expression, is carried out data statistic analysis with variance test, nonparametric data with rank test by SPSS10.0 software parameter data.With P＜0.05 is that difference has significance.
3 results
3.1 ordinary circumstance
Right pedal swelling appears in each group after the modeling, and rat motility occurs and descends walking disorder, phenomenons such as appetite minimizing.The right sufficient sole of the foot appears in 1～2 circumferential portion rat to fester, and the sepage oozing of blood is so note avoiding the diabrosis position when changing dressings.Each diabrosis place healing of forming a scab basically of 3～4 weeks.The Secondary cases swelling of an offside left side sufficient sole of the foot portion, ankle etc. appears in the about the 2nd all rats successively, has reacted the characteristics of the polyarthritis of adjuvant-induced arthritis, shows that animal model makes successfully.
3.2 rat body weight changes
Respectively organize relatively zero difference of rat body weight before the treatment, respectively organize rat body weight after the treatment and change, Chinese drug-treated group and Western medicine group comparison zero difference, two groups with placebo group more all there were significant differences.Chinese drug-treated group, Western medicine group body weight gain amount are greater than placebo group, and the result sees table 1.
Respectively organize rat body weight before and after table 1 treatment and change (unit: g)
Annotate: compare with placebo group,
*P＜0.05; Compare with matched group,
#P＜0.05.
3.3 swelling degree of the paw changes
Respectively organize the rat paw volumetric ratio before the treatment than zero difference, respectively organize the rat paw volume after the treatment and change, Chinese drug-treated group and western medicine group be zero difference relatively, two groups with placebo group more all there were significant differences.Treatment back Chinese drug-treated group, western medicine group rat paw volume are all less than placebo group.The result sees table 2.
Respectively organize rat paw volume-variation (unit: ml) before and after table 2 treatment
Annotate: compare with placebo group,
*P＜0.05; Compare with matched group,
#P＜0.05.
3.4 influence to the joint tissue pathological change
The Chinese drug-treated group synovial cell proliferation, huge to bite the like cell hyperplasia degree the lightest, with matched group group, placebo group significant difference arranged relatively.Placebo group inflammatory cell infiltration, proliferation of fibrous tissue are the most serious, than Chinese drug-treated group, matched group significant difference are arranged.Influence each group inte gration relatively, unknown significance difference to articular cartilage is destructive.Comprehensive each item pathological change, each organizes total mark relatively, Chinese drug-treated group and matched group there was no significant difference, Chinese drug-treated group and placebo group comparing difference are remarkable, and the overall pathological lesion of placebo group is serious, and the result sees table 3.
The comparison of table 3 pair rat arthropathology influence
Annotate: compare with placebo group,
*P＜0.05; Compare with matched group,
#P＜0.05.
4. conclusion
Rat assist agent arthritis is extremely similar with human rheumatoid arthritis, and this animal model is widely used in the research of rheumatoid arthritis.In experiment, the arthritic rat that the makes a difference vigor of ingesting causes ill rat body weight to increases slowly.The degree of controlling arthritic development, easing the pain through efficacious therapy then can be improved the situation of ingesting of suffering from Mus, thus growth promoter relatively normally.
Treatment back Chinese drug-treated group, diclofenac group increase weight greater than the comfort group.Prompting Chinese medicine and Western medicine group all can be improved arthritic pain and dysfunction.
Treatment back Chinese drug-treated group, western medicine group rat paw volume increase all less than placebo group.Point out pharmaceutical composition that is used to treat anemofrigid-damp arthralgia of the present invention and Western medicine all can alleviate and suffer from the Mus pedal swelling, the effect of performance antiinflammatory detumescent.
It is synovitis that the rheumatoid arthritis basic pathology changes.Synovial cell proliferation has reflected the pathological process of rheumatoid arthritis morbidity.Experiment shows that Chinese drug-treated group synovial cell proliferation degree is the lightest, points out drug regimen of the present invention in the inhibition synovial cell proliferation certain advantage to be arranged, and PD is had certain control action.
Inflammatory cell infiltration has reflected the immunoreactive severity of pathological tissue, and the placebo group inflammatory cell infiltration is the most serious.Show that Chinese drug-treated group, Western medicine group have inhibitory action to inflammatory cell infiltration.
The nexine huge equal showed increased of macrophage of biting kind A type synovial cell and the infiltration of lining lower floor in rheumatoid arthritis village plays an important role in destruction of joint.Relatively there were significant differences for Chinese drug-treated group and placebo group, and the huge like cell hypertrophy of biting of placebo group is more serious.Explain that medicinal vesiculation has the outgrowth effect of the macrophage of inhibition.
Proliferation of fibrous tissue has reflected the situation that inflammation destruction back fibrous tissue is divided a word with a hyphen at the end of a line and repaired, and proliferation of fibrous tissue is serious more, and the destruction of articular cartilage is big more.The placebo group proliferation of fibrous tissue is the most serious, than Chinese drug-treated group, matched group significant difference is arranged.Chinese drug-treated group and Western medicine group be no significant difference relatively, and both are similar to suppressing proliferation of fibrous tissue aspect effect.
The minimizing of chondrocyte is the pathological lesion in late period of rheumatoid arthritis.Cartilage degeneration, ossified appears in pathology notification portion case, vasodilation in the cartilage, blood stasis, but normal articular cartilage is in the majority.Each organizes unknown significance difference, possibly be that modeling, treatment time are short, does not cause serious cartilage and bone destruction of later stage as yet.
Through each group total mark relatively, the overall pathological lesion of placebo group is serious, and drug regimen of the present invention and western medicine group all can improved pathological lesion in various degree, thereby play the effect of treatment of arthritis.
Embodiment 3
The present invention treats the clinical research of wind cold wetness type rheumatoid arthritis
1. object
Select rheumatoid arthritis (RA) patient 51 examples; Be divided into conventional therapy group (matched group) at random and add medicine composite for curing group of the present invention (treatment group) with conventional therapy; At aspect no significant differences such as sex, age, the course of disease, stadium, have comparability between two groups, see table 4.
Table 4 liang group patient physical data
Wherein, RA diagnostic criteria (with reference to the diagnostic criteria of Americanism damp disease association (ACR) in 1987 formulation) is:
A morning is stiff: the joint and on every side stiff sense continue 1h (course of disease >=6 weeks) at least;
B3 arthritis individual or zone more than 3: the doctor observes in following 14 zones (PIP on left side or right side, metacarpophalangeal joints, wrist, elbow, knee joint, ankle and metatarsophalangeal joints) and involves 3, and while soft tissue swelling or hydrops (not being simple bone protuberance) (course of disease >=6 weeks);
The c cheirarthritis: wrist, the palm refer to or the PIP inflammation in, have an arthroncus (course of disease >=6 weeks) at least;
D symmetry arthritis: joint, both sides (when bilateral PIP, metacarpophalangeal joints and metatarsophalangeal joints are got involved, not necessarily absolute symmetry) (course of disease >=6 weeks) of getting involved simultaneously;
The e rheumatoid nodules: the doctor observes at the apophysis position, and subcutaneous nodule is arranged around extensor surface or the joint;
F rheumatoid factor positive (titre＞1: 32): any detection method proof serum rheumatoid factor (SRF) content is unusual, and the positive rate of this method in normal population is less than 5%;
The g radiology changes: have typical rheumatoid arthritis radiology to change in the postero-anterior position of hands and wrist on mutually, must comprise bone erosion or the joint and be close to the position clear and definite sclerotin decalcification is arranged of getting involved.
More than 7 satisfy more than 4 or 4, and to get rid of other arthritis be diagnosable RA.
Stadium criteria for classification (Chinese rheumatology magazine, 1998; 2 (2): 87. " rheumatoid arthritis stadium criteria for classification, rheumatoid arthritis functional classification standards " .) be:
I phase (in early days) X line is taken the photograph sheet does not have destructive the change, and osteoporosis can be arranged.
II phase (mid-term) X-ray film osteoporosis or slight cartilage destruction; Joint motion is limited, but does not have the joint distortion, the juxtra-articular amyotrophy of getting involved, and soft tissue lesions outside the joint is like rheumatoid nodules and tenosynovitis.
III phase (serious phase) X line is taken the photograph sheet except that osteoporosis is arranged, and also has cartilage and osteoclasia; Joint deformity, like subluxation, ulnar side deflection or joint hyperextension, but do not have bone fibrosis or bone property strong from; Extensively amyotrophy; Soft tissue lesions outside the joint.
IV phase (whole latter stage) bone fibrosis or bone property are certainly strong; Possesses the interim standard of III.
The dialectical standard of traditional Chinese medical science wind cold wetness type (with reference to 2006 " common rheumatism combination of Chinese and Western medicine diagnosis and treatment summary ") is:
Main symptom: arthralgia acid is expanded, and joint stuffiness is met wind and cold and then increased the weight of, and local color of the leather is not red, and that touches is not hot, tastelessness and no thirst, and body of the tongue is light red, Tai Bai or thin greasy, deep-slow pulse.
2. method
2.1 Therapeutic Method
Matched group: use conventional therapy: the compound recipe moon is joined injection 20ml+5% glucose injection or normal saline 500ml, and quiet, every day 1 time, totally 20 days, after resting 7 days, part patient gave for the 2nd course of treatment, methotrexate 10mg, oral, 1 time weekly.Use the hormone person when being admitted to hospital, continue oral and the maintenance dose that minimizes gradually.The obvious person of arthralgia gives mobic 7.5mg, and 1/ day, tcm syndrome differentiation and treatment.
Treatment group: on the treatment of control group basis, add drug regimen of the present invention and method for using, the 1g ointment is affixed on the human acupoint, totally 3 times.Make medicament: the unguentum that embodiment 1 is prepared.Acupoints: by patient sick parts and meridian line to determine the appropriate medicine moxibustion points, such as the wrist to take Yang Chi, Yang River, etc.; shoulder to take arm Er, shoulder Chen, etc.; elbow take Quchi chize etc. ; take hip thigh clearance, ring jump, etc.; knee taken within liangqiu, Hedingshan etc.; lumbosacral take Huatuojiaji, Shenshu, ring jump, etc., can also take Ashi.Shared: big vertebra, Quchi, sp 9, rich and prosperous etc.
2.2 evaluation index
2.2.1 direct observation project
The stiff time of arthralgia index, articular pain index, joint swelling index, function of joint index, moving obstacle index, morning and the arthralgia number of each case of observed in detail record.With reference to the clinical examination stage division of " therapy of combining Chinese and Western medicine rheumatism " book in 1989, according to the performance of patient joint symptom and sign, by do not have, light, in, the difference of heavy degree quantizes respectively, and is specific as follows:
The arthralgia standard of index: 0 no pain; 1 motionless not bitterly, the activity hypodynia; 2 motionless also pains, the activity postemphasis; 3 sharp aches, joint motion is obviously limited because of pain.
The articular pain standard of index: 0 no tenderness; 1 mild tenderness; Tell pain and the performance of fear is arranged during 2 compressings; 3 refuse to do the tenderness inspection.
Joint swelling index standard: 0 no swelling; 1 arthroncus, but do not surpass juxtra-articular apophysis part as yet; 2 arthroncuss are obvious, and are equal with the apophysis part; 3 joint height swelling, swelling place are higher than near apophysis part.
The moving obstacle standard of index: 0 is accessible; 1 joint motion limited 1/5; 2 joint motions limited 2/5; 3 joint motions limited 3/5; 4 joint motions limited 4/5 or tetanic fixing.
The allomeric function standard of index: 0 is normal, any activity of competent fully every day; 1 can be engaged in normal activity, but joint limitation of activity and pain are arranged; 2 can only take care of oneself lives or be engaged in the minority occupational activity; 3. be unable to leave the bed or wheelchair the life of can not taking care of oneself.
Morning stiff integration standard: 0 no morning deadlock; The stiff time in 1 morning is in 1 hour; The stiff time in 2 mornings is 1-2 hour; The stiff time in 3 mornings was greater than 2 hours.
According to exponential difference before and after the patient treatment, judge patient's symptom, sign improvement degree, the evaluation curative effect.
2.2.2 lab index:
(a) curative effect index: the variation of erythrocyte sedimentation rate (ESR), c reactive protein (CRP), rheumatoid factor (RF), immunoglobulin (Ig), complement (C).
(b) safety indexes: routine blood test, routine urinalysis, stool routine, liver function (ALT), renal function (BUN, Cr).
Wherein, the mode of following up a case by regular visits to is: blood of check in per 3 months, routine urinalysis, liver function, F5R, CRP, RF, 1 year check X line hands, carpal joint sheet and former contrast, itemized record change of illness state, drug side effect simultaneously.
2.3 curative effect judging standard
With reference to " criterion of therapeutical effect of new Chinese medicine clinical research guideline new Chinese medicine treatment arthromyodynia ".Total mark * 100% before clinical efficacy=(total mark before the treatment-treatment back total mark) ÷ treatment is divided into clinical cure, produce effects, effective and invalid.
Clinical cure: total mark improves >=90%; Cardinal symptom disappears basically, and it is normal that functional activity recovers, and main inflammatory index ESR, CRP are normal.
Produce effects: total mark improves >=70%; Cardinal symptom is most of to disappear, and function of joint is recovered basically, can participate in operate as normal or work, and main inflammatory index ESR, CRP obviously improve.
Effectively: total mark improves >=20%; Cardinal symptom obviously alleviates, and main function of joint makes progress, and life can take care of oneself by not taking care of oneself to transfer to, and work capacity is recovered to some extent, and main inflammatory index ESR, CRP make moderate progress.
Invalid: total mark improves≤20%; With the treatment before compare, each side does not all have obvious progress.
2.4 statistical procedures
Use SPSS10.0 software and do statistical analysis, measurement data adopts the t check, and enumeration data adopts X 2 test.
3. result
Treatment group total effective rate 96.29%, obvious effective rate 37.04%; Matched group total effective rate 95.83%, 29.16%, two group of total effective rate no significant difference of obvious effective rate, and obvious effective rate there were significant differences, see table 5.
Table 5 liang group clinical efficacy relatively
With the matched group ratio,
*P＜0.05.
With compare before the treatment, all there are improvement two groups of patient's pain indexes, tenderness index, swelling index, allomeric function index, moving obstacle exponential sum stiff times in morning.Treatment group and matched group relatively, the improvement in stiff time of pain index, tenderness index, swelling index and morning of patient obviously is superior to matched group (P＜0.05); At the allomeric function index, moving obstacle is exponential improve aspect with matched group do not have significant difference, see table 6.
The integration variation
of the table 6 liang forward and backward patient's local joint symptom of group treatment, sign index
With preceding relatively △ p＜0.05 of treatment, △ △ p＜0.01; With the matched group ratio,
*P＜0.05.
Behind two groups of patient treatments in the serum ESR and CRP content remarkable decline is all arranged, the treatment group is seen table 7 obviously being superior to matched group (P＜0.05) aspect the decline of erythrocyte sedimentation rate index.
The variation
of ESR, CRP before and after the table 7 liang group treatment
With the matched group ratio,
*P＜0.05; Preceding with treatment than △ p＜0.05, △ △ p＜0.01.
There is obvious decline (P＜0.05) the drug regimen treatment of the present invention back preceding immunoglobulin of treatment, sees table 8.
Immunoglobulin in pilots
before and after the treatment of table 8 medicinal vesiculation treatment group
Relatively preceding with treatment
*P＜0.05.
And, all do not have great adverse events behind the 51 routine patient treatments and take place.Blister appearred in local skin after medicine composite for curing group of the present invention had 2 routine point applications, and diabrosis stops pasting back skin and heals very soon.Find routine blood test, routine urinalysis, stool routine, the hepatic and renal function treatment no abnormal change in back in the observation of laboratory safety property index.
This result of study shows that drug regimen treatment group obvious effective rate of the present invention is apparently higher than matched group; The treatment group obviously is superior to matched group (P＜0.05) in the improvement of patient's stiff time of pain index, tenderness index, swelling index and morning, explains that drug regimen of the present invention has obvious facilitation to the improvement of patient's arthritic symptom and sign.The phase reaction index was closely related with rheumatismal activeness when ESR was a kind of easy and simple to handle, good reproducibility commonly used clinically acute, and the state of an illness increases the weight of then that erythrocyte sedimentation rate speeds, and the state of an illness when alleviating erythrocyte sedimentation rate can recover normal.It is obvious than matched group that this result of study shows that treatment group patient ESR descends, and explains that drug regimen of the present invention and Therapeutic Method can assist antirheumatic thing disease controlling, effectively suppresses arthritis, and sb.'s illness took a favorable turn has positive effect to accelerating.
RA is to be the autoimmune disease of main clinical manifestation with the symmetry polyarthritis, often can cause destruction of joint and joint deformity.Research shows that pro-inflammatory cytokines such as IL-1 β, TNF-A, IL-6 play an important role in the RA pathogenic process.IL-1 β raises can promote IL-6 and other production of cytokines among expression of MMPs mRNA and the synovial cell, thereby causes the aggravation of osteoarticular destruction and inflammation.Reports such as Fang Jianqiao adopt (medicinal vesiculation) treatment of applying ointment or plaster of acupoints on Du channel Mylabris cream can suppress the level of collagen immunization mice IL-1 β effectively, can obviously suppress the generation of mice CIA, significantly reduce arthritis index.IL-2 is the important cytokine of participating in the immunity of organism regulation and control, and IL-2 produces minimizing or function is obstructed, and can cause the immunity of organism regulatory function disorderly.RA patient is significantly low at active stage IL-2, is prone to cause the generation of inflammation.The report medicinal vesiculation list cave gate of vitality, cvs such as Bao Yimei can improve AA rat IL-2 level.This shows, drug regimen of the present invention and Therapeutic Method in treatment RA, IL-1 β that can be through reducing the patient with improve IL-2 and control the aggravation of osteoarticular destruction and inflammation.And medicine composite for curing of the present invention can reduce the level of patient IgA, IgG, IgM (P＜0.05), points out drug regimen of the present invention that RA patient is had good immunoregulation effect
Embodiment 4
The present invention treats the clinical observation of ankylosing spondylitis
1. object
Select ankylosing spondylitis (AS) patient 40 examples; Be divided into conventional therapy group (matched group) at random and add medicine composite for curing group of the present invention (treatment group) with conventional therapy; At aspect no significant differences such as sex, age, the course of disease, stadium, have comparability between two groups, see table 9.
Table 9 liang group patient physical data
Wherein, AS diagnostic criteria (with reference to the AS diagnostic criteria of New York revisions in 1984) is:
A. clinical criteria
(1) lumbago is refused to budge and continuously alleviate after the activity more than 3 months morning, and the back of having a rest does not have and alleviates;
(2) lumbar vertebra frontal plane and sagittal plane limitation of activity (forward and backward, lateroflexion is limited);
(3) the thorax mobility be lower than corresponding age, sex the normal person (can＜2.5cm).
B. radiology standard: sacroiliitis, bilateral >=II level or one-sided III-IV level.The sacroiliitis grade scale is following:
0 grade: normal;
I level: suspicious;
II level: be mile abnormality, erosion, sclerosis arranged but the joint space is normal;
The III level: unusual for obviously, there are 1 of erosion, sclerosis, joint space broadening or narrow, partial tetanus etc. (or more than) to change;
IV level: be severely subnormal, i.e. the completeness ankylosis.
The C diagnostic criteria
(1) affirms AS: meet the radiology standard, add 1 or 1 above clinical criteria person;
(2) maybe AS: meet 3 clinical criteria, or meet the radiology standard and without any clinical criteria person.
The dialectical standard of traditional Chinese medical science wind cold wetness type is (with reference to " common rheumatism combination of Chinese and Western medicine diagnosis and treatment summary " in 2006
Main symptom: lower back and joint cold type of pain, it is unfavorable to change one's position, and increases the weight of gradually, overcast and rainy whenever or sense cold back aggravation, sore spot happiness temperature, fatigue and asthenia.Light red tongue is fat, and tongue is bored with in vain and moistens, and pulse condition is heavy tight or late heavy.
2. method
2.1 Therapeutic Method
Matched group: use conventional therapy: the compound recipe moon is joined injection 20ml+5% glucose injection or normal saline 500ml, and quiet, every day 1 time, totally 20 days, after resting 7 days, part patient gave for the 2nd course of treatment, methotrexate 10mg, oral, 1 time weekly.Use the hormone person when being admitted to hospital, continue oral and the maintenance dose that minimizes gradually.The obvious person of arthralgia gives mobic 7.5mg, and 1/ day, tcm syndrome differentiation and treatment.
Treatment group: on the treatment of control group basis, add drug regimen of the present invention and method for using, the 1g ointment is affixed on the acupuncture point, upper body, totally 3 times.Make medicament: the unguentum that embodiment 1 is prepared.Acupoint selection: shared acupuncture point: big vertebra, Quchi, sp 9, rich and prosperous.Another site of pain by the patient and the meridian line to determine the appropriate medicine moxibustion points: If the wrist to take Yang Chi, Yang River, etc.; shoulder to take arm Er, shoulder Chen, etc.; elbow take Quchi chize etc.; hip Take thigh clearance, ring jump, etc.; knee taken within liangqiu, Hedingshan etc.; lumbosacral take Huatuojiaji, Shenshu, jump rings, etc., can also take Ashi.
2.2 evaluation index
2.2.1 direct observation project
The stiff time of arthralgia index, articular pain index, function of joint index, moving obstacle index, morning and the arthralgia number of each case of observed in detail record.With reference to the clinical examination stage division of " therapy of combining Chinese and Western medicine rheumatism " book in 1989, according to the performance of patient joint symptom and sign, by do not have, light, in, the difference of heavy degree quantizes respectively, and is specific as follows:
The arthralgia standard of index: 0 no pain; 1 motionless not bitterly, the activity hypodynia; 2 motionless also pains, the activity postemphasis; 3 sharp aches, joint motion is obviously limited because of pain.
The articular pain standard of index: 0 no tenderness; 1 mild tenderness; Tell pain and the performance of fear is arranged during 2 compressings; 3 refuse to do the tenderness inspection.
Joint swelling index standard: 0 no swelling; 1 arthroncus, but do not surpass juxtra-articular apophysis part as yet; 2 arthroncuss are obvious, and are equal with the apophysis part; 3 joint height swelling, swelling place are higher than near apophysis part.
The moving obstacle standard of index: 0 is accessible; 1 joint motion limited 1/5; 2 joint motions limited 2/5; 3 joint motions limited 3/5; 4 joint motions limited 4/5 or tetanic fixing.
The allomeric function standard of index: 0 is normal, any activity of competent fully every day; 1 can be engaged in normal activity, but joint limitation of activity and pain are arranged; 2 can only take care of oneself lives or be engaged in the minority occupational activity; 3. be unable to leave the bed or wheelchair the life of can not taking care of oneself.
Morning stiff integration standard: 0 no morning deadlock; The stiff time in 1 morning is in 1 hour; The stiff time in 2 mornings is 1-2 hour; The stiff time in 3 mornings was greater than 2 hours.
According to exponential difference before and after the patient treatment, judge patient's symptom, sign improvement degree, the evaluation curative effect.
2.2.2 lab index:
(a) curative effect index: the variation of erythrocyte sedimentation rate (ESR), c reactive protein (CRP), HLAB27, immunoglobulin (Ig), complement (C).
(b) safety indexes: routine blood test, routine urinalysis, stool routine, liver function (ALT), renal function (BUN, Cr).
Wherein, the mode of following up a case by regular visits to is: blood of check in per 3 months, routine urinalysis, liver function, CRP, ESR, 1 year check X skiagram and former contrast, itemized record change of illness state, drug side effect simultaneously.
2.3 curative effect judging standard
With reference to " criterion of therapeutical effect of new Chinese medicine clinical research guideline new Chinese medicine treatment arthromyodynia ".Total mark * 100% before clinical efficacy=(total mark before the treatment-treatment back total mark) ÷ treatment is divided into clinical cure, produce effects, effective and invalid.
Clinical cure: total mark improves >=90%; Cardinal symptom disappears basically, and it is normal that functional activity recovers, and main inflammatory index ESR, CRP are normal.
Produce effects: total mark improves >=70%; Cardinal symptom is most of to disappear, and function of joint is recovered basically, can participate in operate as normal or work, and main inflammatory index ESR, CRP obviously improve.
Effectively: total mark improves >=20%; Cardinal symptom obviously alleviates, and main function of joint makes progress, and life can take care of oneself by not taking care of oneself to transfer to, and work capacity is recovered to some extent, and main inflammatory index ESR, CRP make moderate progress.
Invalid: total mark improves≤20%; With the treatment before compare, each side does not all have obvious progress.
2.4 statistical procedures
Use SPSS10.0 software and do statistical analysis, measurement data adopts the t check, and enumeration data adopts X 2 test.
3. result
Among the 40 routine patients, treatment group total effective rate 94.74%, obvious effective rate 42.11%; Matched group total effective rate 95.23%, 33.33%, two group of total effective rate no significant difference of obvious effective rate, and obvious effective rate there were significant differences (P＜0.05), see table 10.
Table 10 liang group clinical efficacy relatively
With the matched group ratio,
*P＜0.05.
With compare before the treatment, all there are improvement two groups of patient's pain indexes, tenderness index, allomeric function index, moving obstacle exponential sum stiff times in morning.The treatment group patient's pain, tenderness and morning stiff improve aspect the treatment group obviously be superior to matched group (P＜0.05), see table 11.
The integration variation
of the table 11 liang forward and backward patient's local joint symptom of group treatment, sign index
With preceding relatively △ p＜0.05 of treatment, △ △ p＜0.01; With the matched group ratio,
*P＜0.05.
Behind two groups of patient treatments in the serum ESR and CRP content remarkable decline is all arranged, the treatment group is seen table 12 all being superior to matched group (P＜0.05) aspect the decline of erythrocyte sedimentation rate and CRP.
The variation
of ESR, CRP before and after the table 12 liang group treatment
With the matched group ratio,
*P＜0.05; Preceding with treatment than △ △ p＜0.01.
All there is decline (P＜0.05) the treatment group treatment back preceding immunoglobulin of treatment, sees table 13.
Immunoglobulin in pilots
before and after the treatment of table 13AS treatment group
Relatively preceding with treatment
*P＜0.05.
And, all do not have great adverse events behind the 40 routine patient treatments and take place.Blister appearred in local skin after the treatment group had 2 routine point applications, and diabrosis stops pasting back skin and heals very soon.Find routine blood test, routine urinalysis, stool routine, the hepatic and renal function treatment no abnormal change in back in the observation of laboratory safety property index.
This result of study shows that the total effective rate and the matched group of treatment group do not have significant difference, but the obvious effective rate of treatment group is apparently higher than matched group.The treatment group obviously is superior to matched group in pain index, tenderness index, the improvement of allomeric function exponential sum stiff time in morning.Explain that drug regimen of the present invention and method for using thereof have obvious facilitation to the improvement of arthritic symptom and sign.
We have observed the change of acute inflammation index ESR before and after the AS patient treatment, CRP.Discovery all has remarkable decline through giving behind the regular treatment two groups of patients serum ESR and CRP content, and the treatment group all is being superior to matched group aspect the decline of ESR and CRP.The phase reaction index was closely related with rheumatismal activeness when ESR was a kind of easy and simple to handle, good reproducibility commonly used clinically acute, and the state of an illness increases the weight of then that erythrocyte sedimentation rate speeds, and the state of an illness when alleviating erythrocyte sedimentation rate can recover normal; CRP also is the index of the responsive reflection AS state of an illness, and some researchs abroad show that CRP possibly be associated with rheumatism disease index, stiff time in morning, grip, arthralgia, joint swelling index, erythrocyte sedimentation rate etc.This result of study shows that treatment group patient ESR and CRP decline aspect are all obvious than matched group, explains that drug regimen of the present invention and method for using thereof can assist antirheumatic thing disease controlling, effectively suppresses arthritis, and sb.'s illness took a favorable turn has positive effect to accelerating.
Think that at present the generation of AS is all relevant with self-immunprocess with sustainable development.And pharmaceutical composition of the present invention can reduce the level of AS patient IgA, IgG, IgM (P＜0.05), and prompting the present invention has good immunoregulation effect to AS patient.
Embodiment 5
The present invention treats the clinical observation of knee osteoarthritis
1. object
The patient is totally 32 examples, wherein male 14 examples, women 18 examples; 45～76 years old age, 58.8 years old mean age; Unilateral knee joint 20 examples of falling ill, bilateral 12 examples, totally 44 knee joints; The course of disease 5 months～10 years, average 4.2 years.
Wherein, diagnostic criteria is with reference to the diagnostic criteria of American Rheumatism Association to knee osteoarthritis:
1. most of date gonalgias in 1 month;
2. sound is arranged during the knee joint activity;
3. knee joint deadlock≤30min in morning;
4. age >=38 year old;
5. snap is accompanied in knee joint swelling;
6. snap is not accompanied in knee joint swelling.
At least exist and 1. 2. 3. 4. or 1. 2. 3. 5. or 1. 6. can be diagnosed as knee joint KOA.This is organized 32 examples and all meets above diagnostic criteria, and gets rid of and can not accomplish complete treatment observation process person.
2. method
2.1 Therapeutic Method
Adopt the prepared unguentum of embodiment 1, ointment is spread out on adhesive plaster, form the circular mastic of the about 1cm of diameter, be applied to following acupuncture point: big vertebra, Quchi, sp 9, rich and prosperous, interior Liangqiu, Heding.Application plaster is affixed on acupuncture point 2h～3h does not wait, moxibustion time length varies with each individual, per 10 days 1 time.Visible rubescent, the blister of local skin in treatment back punctures blister with sterile needle, and BF is drained, and uses iodophor disinfection, keeps skin clean dry, protects from infection 2 sterilizations draining every day.10 days blanking times, 3 times was 1 course of treatment.
2.2 efficacy assessment standard
With the addition of scoring respectively of pain, function, action degree, 11～12 are divided into excellently evaluation of clinical curative effect with reference to the gonalgia of Yang and function scoring, and 9～10 are divided into very, and 6～8 are divided into, 3～5 be divided into poor.Specifically see table 14
Table 14 gonalgia and function scoring pain functional activity degree integration
3. result
This organize 32 examples through 6～36 months follow up a case by regular visits to average 13.2 months; The result is according to the gonalgia and function scoring wherein excellent 16 routine 22 knee joints, good 8 routine 11 knee joints, in 5 routine 7 knee joints, differ from 3 routine 4 knee joints, total acceptance rate is 75.00%.Do not have 1 routine joint severe complications such as infection take place.
Above content is to combine concrete preferred implementation to the further explain that the present invention did, and can not assert that practical implementation of the present invention is confined to these explanations.For the those of ordinary skill of technical field under the present invention, under the prerequisite that does not break away from the present invention's design, can also make some simple deduction or replace, all should be regarded as belonging to protection scope of the present invention.
Claims (8)
1. pharmaceutical composition that is used to treat anemofrigid-damp arthralgia is characterized in that: its raw material is by Semen Strychni, Herba speranskiae tuberculatae, and Semen Sinapis Albae, Cortex Cinnamomi, Radix Aconiti Preparata, Rhizoma Arisaematis, Fructus Evodiae, Rhizoma Corydalis, Radix Clematidis, Herba Asari, Borneolum Syntheticum, Moschus is formed.
2. the pharmaceutical composition that is used to treat anemofrigid-damp arthralgia according to claim 1 is characterized in that, its raw material comprises in weight portion: Semen Strychni 500-750 part, Herba speranskiae tuberculatae 500-750 part; Semen Sinapis Albae 500-750 part, Cortex Cinnamomi 300-450 part, Radix Aconiti Preparata 300-450 part, Rhizoma Arisaematis 300-450 part; Fructus Evodiae 200-300 part, Rhizoma Corydalis 200-300 part, Radix Clematidis 200-300 part; Herba Asari 100-150 part, Borneolum Syntheticum 100-150 part, Moschus 3-4.5 part.
3. the pharmaceutical composition that is used to treat anemofrigid-damp arthralgia according to claim 2 is characterized in that, its raw material comprises in weight portion: 500 parts of Semen Strychni, 500 parts of Herba speranskiae tuberculataes; 500 parts of Semen Sinapis Albaes, 300 parts of Cortex Cinnamomis, 300 parts of Radix Aconiti Preparatas, 300 parts of Rhizoma Arisaematis; 200 parts of Fructus Evodiaes, 200 parts of Rhizoma Corydalis, 200 parts of Radix Clematidis; 100 parts of Herba Asaris, 100 parts of Borneolum Syntheticums, 5 parts in Moschus.
4. according to each described pharmaceutical composition that is used to treat anemofrigid-damp arthralgia of claim 1-3, it is characterized in that: said dosage form is to add excipient after raw material grinds to the powder to be made as unguentum.
5. the pharmaceutical composition that is used to treat anemofrigid-damp arthralgia according to claim 4 is characterized in that: said excipient is a vaseline.
6. the described method for using that is used to treat the pharmaceutical composition of anemofrigid-damp arthralgia of claim 1-5 is characterized in that: said pharmaceutical composition is affixed on the human acupoint.
7. method for using according to claim 6 is characterized in that: after being affixed on said pharmaceutical composition on the human acupoint, keep 2h-3h, paste the medicine place and avoid extruding; Because of individual physique difference, the patient can be scorching hot rubescent according to local appearance after pasting medicine, or slight twinge can be removed the subsides medicine voluntarily.There is scorching hot twinge to feel bad like the part and also can removes medicine in advance.Cause blister like drug of topical application overlong time, should protect wound surface, avoid scratching infection, can put scald ointment on the skin.Cold water was not being wanted in the position of the drug of topical application in 10 hours.
8. method for using according to claim 7 is characterized in that: whenever used once said pharmaceutical composition at a distance from 10 days, 3 times was 1 course of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100186800A CN102552593B (en) | 2012-01-19 | 2012-01-19 | Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100186800A CN102552593B (en) | 2012-01-19 | 2012-01-19 | Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552593A true CN102552593A (en) | 2012-07-11 |
| CN102552593B CN102552593B (en) | 2013-07-17 |
Family
ID=46400047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100186800A Expired - Fee Related CN102552593B (en) | 2012-01-19 | 2012-01-19 | Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552593B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106267080A (en) * | 2016-08-31 | 2017-01-04 | 唐秀宗 | For Chinese herbal medicine sticking acupuncture point and preparation method thereof, using method |
| CN109663080A (en) * | 2017-10-17 | 2019-04-23 | 张猛 | A kind of smoked medicament and its application method for washing ankylosing spondylitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049387A (en) * | 2007-05-16 | 2007-10-10 | 陈昌虎 | Composition of Chinese traditional medicine for treating rheumatic bone disease |
-
2012
- 2012-01-19 CN CN2012100186800A patent/CN102552593B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049387A (en) * | 2007-05-16 | 2007-10-10 | 陈昌虎 | Composition of Chinese traditional medicine for treating rheumatic bone disease |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106267080A (en) * | 2016-08-31 | 2017-01-04 | 唐秀宗 | For Chinese herbal medicine sticking acupuncture point and preparation method thereof, using method |
| CN109663080A (en) * | 2017-10-17 | 2019-04-23 | 张猛 | A kind of smoked medicament and its application method for washing ankylosing spondylitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552593B (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101214286B (en) | Chinese medicine white spirit preparations for effectively treating rheumatic pain diseases | |
| CN102552593B (en) | Chinese medicinal composition for treating wind-cold-dampness arthralgia and using method thereof | |
| CN103877334A (en) | Chinese medicinal liquor for treating rheumatoid arthritis and preparation method thereof | |
| CN104825786B (en) | A kind of Chinese medicine composition for treating neck-shoulder pain, lumbago and leg pain | |
| CN100421687C (en) | Chinese medicine for treating kidney insufficiency | |
| CN102258696B (en) | Compound traditional Chinese medicine for treating undifferentiated spondyloarthropathy (uSpA) and application thereof | |
| CN102188496A (en) | Chinese medicine for treating ankylosing spondylitis and preparation method thereof | |
| CN1772245A (en) | Snake medicinal wine for health care massage and its application | |
| CN110787278B (en) | Traditional Chinese medicine external application plaster for treating tenosynovitis and preparation method thereof | |
| CN114652674A (en) | Blood circulation promoting and pain relieving ointment and preparation method thereof | |
| CN104208369B (en) | Five-stem ease pill for treating gout | |
| CN1270053A (en) | Medicine for treating rheumatic arthritis and hyperosteogeny and preparing process thereof | |
| CN106109930A (en) | A kind of Chinese medicine preparation treating lumbago and skelalgia and preparation method | |
| CN105326926A (en) | External pharmaceutic preparation for treating aponeurotic channel diseases, preparation method and application thereof | |
| CN100427132C (en) | Traditional Chinese medicine for treating rheumatism and its preparing process | |
| CN1939526A (en) | Stasis arthralgia and its production | |
| CN1765381A (en) | Conditioning qi-invigorating weight-reducing extract | |
| CN102258589B (en) | Deer blood medicinal wine for treating rheumatoid arthritis | |
| CN1228064C (en) | Externally appied medicine for relieving pain and diminishing inflammation | |
| CN1299762C (en) | Chinese medicinal preparation for treating atrophic arthritis | |
| CN101057951B (en) | Plaster for auxiliary curing rheumatoid disease and its preparing method | |
| CN1582961A (en) | Improved Chinese medicinal paste for arthralgia and its preparation | |
| CN105727118A (en) | Medicinal liquor for treating wind-cold-dampness arthralgia and preparation method for medicinal liquor | |
| CN105125995A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia | |
| CN104758400A (en) | External medicinal liquor for treating rheumatism and arthritis and preparation method of external medicinal liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20180119 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |